Paper40260239
Mechanisms of HDACs in cancer development.
Zhang Y and 4 others. Front Immunol, 2025. Cited by 46 papers, by iCite.
Cite this record
ConductScience Library. Mechanisms of HDACs in cancer development. Papers, record 40260239. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40260239
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Neoplasms | Major topic |
| Histone Deacetylase Inhibitors | Major topic |
| Histone Deacetylases | Major topic |
| Humans | |
| Epigenesis, Genetic | |
| Animals | |
| Tumor Microenvironment | |
| Antineoplastic Agents |
Source PubMed
References203
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 23939379 | Histone deacetylase regulation of ATM-mediated DNA damage signaling. | Mol Cancer Ther | 2013 | https://conductscience.org/library/papers/23939379 | PubMed |
| 2 | 21596753 | miR-200a regulates SIRT1 expression and epithelial to mesenchymal transition (EMT)-like transformation in mammary epithelial cells. | J Biol Chem | 2011 | https://conductscience.org/library/papers/21596753 | PubMed |
| 3 | 16511565 | Metastasis-associated protein 1 enhances stability of hypoxia-inducible factor-1alpha protein by recruiting histone deacetylase 1. | EMBO J | 2006 | https://conductscience.org/library/papers/16511565 | PubMed |
| 4 | 26240284 | Histone Deacetylase 10 Regulates the Cell Cycle G2/M Phase Transition via a Novel Let-7-HMGA2-Cyclin A2 Pathway. | Mol Cell Biol | 2015 | https://conductscience.org/library/papers/26240284 | PubMed |
| 5 | 30582912 | Histone deacetylase 8 triggers the migration of triple negative breast cancer cells via regulation of YAP signals. | Eur J Pharmacol | 2019 | https://conductscience.org/library/papers/30582912 | PubMed |
| 6 | 21685935 | EZH2 supports nasopharyngeal carcinoma cell aggressiveness by forming a co-repressor complex with HDAC1/HDAC2 and Snail to inhibit E-cadherin. | Oncogene | 2012 | https://conductscience.org/library/papers/21685935 | PubMed |
| 7 | 28126962 | Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study. | Haematologica | 2017 | https://conductscience.org/library/papers/28126962 | PubMed |
| 8 | 25131830 | Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. | Nat Rev Drug Discov | 2014 | https://conductscience.org/library/papers/25131830 | PubMed |
| 9 | 21247901 | Histone deacetylases 9 and 10 are required for homologous recombination. | J Biol Chem | 2011 | https://conductscience.org/library/papers/21247901 | PubMed |
| 10 | 10597302 | Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. | Oncogene | 1999 | https://conductscience.org/library/papers/10597302 | PubMed |
| 11 | 28860342 | CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial. | Haematologica | 2017 | https://conductscience.org/library/papers/28860342 | PubMed |
| 12 | 12494463 | Histone deacetylase inhibitor trichostatin A induces cell-cycle arrest/apoptosis and hepatocyte differentiation in human hepatoma cells. | Int J Cancer | 2003 | https://conductscience.org/library/papers/12494463 | PubMed |
| 13 | 23088871 | Intrinsic and extrinsic apoptotic pathway signaling as determinants of histone deacetylase inhibitor antitumor activity. | Adv Cancer Res | 2012 | https://conductscience.org/library/papers/23088871 | PubMed |
| 14 | 35170082 | Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T-cell lymphoma in a Chinese population: A multicenter phase II trial. | Am J Hematol | 2022 | https://conductscience.org/library/papers/35170082 | PubMed |
| 15 | 35552447 | Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer. | Oncologist | 2022 | https://conductscience.org/library/papers/35552447 | PubMed |
| 16 | 30868056 | Histone deacetylase 2 is involved in DNA damage-mediated cell death of human osteosarcoma cells through stimulation of the ATM/p53 pathway. | FEBS Open Bio | 2019 | https://conductscience.org/library/papers/30868056 | PubMed |
| 17 | 22961641 | Histone deacetylase inhibitors stimulate dedifferentiation of human breast cancer cells through WNT/β-catenin signaling. | Stem Cells | 2012 | https://conductscience.org/library/papers/22961641 | PubMed |
| 18 | 22301920 | HDAC5 is required for maintenance of pericentric heterochromatin, and controls cell-cycle progression and survival of human cancer cells. | Cell Death Differ | 2012 | https://conductscience.org/library/papers/22301920 | PubMed |
| 19 | 25107918 | Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors. | Clin Cancer Res | 2014 | https://conductscience.org/library/papers/25107918 | PubMed |
| 20 | 15301879 | Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. | Lung Cancer | 2004 | https://conductscience.org/library/papers/15301879 | PubMed |
Cited by33
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 46 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42948158 | New sulfonamide derivatives as HDAC inhibitors and apoptosis inducers: design, synthesis, in silico study and anticancer evaluation. | RSC Adv | 2026 | https://conductscience.org/library/papers/42948158 | PubMed |
| 42883867 | Targeting Aromatase and HDACs in Hormone Receptor-Positive Breast Cancer: Molecular Interplay, Endocrine Resistance and Therapeutic Opportunities. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42883867 | PubMed |
| 42830998 | Membrane-associated HDAC11: A potential new therapeutic targeting compartment in cancer cells. | Biochem Biophys Rep | 2026 | https://conductscience.org/library/papers/42830998 | PubMed |
| 42792755 | Epigenetic Plasticity in Triple-Negative Breast Cancer: Mechanisms of Therapy Resistance, Biomarkers, and Therapeutic Vulnerabilities. | Biomedicines | 2026 | https://conductscience.org/library/papers/42792755 | PubMed |
| 42750032 | The roles of chromatin remodeling and 3D genome organization in cancers: from mechanistic insights to emerging treatment options. | Mol Cancer | 2026 | https://conductscience.org/library/papers/42750032 | PubMed |
| 42661166 | Exploration of novel hydroxamic acid-based candidates integrating chalcone scaffold cap as multitarget HDAC inhibitors: design, anti-prostatic cancer assessment, in silico docking and molecular dynamic simulation. | J Enzyme Inhib Med Chem | 2026 | https://conductscience.org/library/papers/42661166 | PubMed |
| 42517085 | HDAC inhibitors as ferroptosis sensitizers in cancer: Epigenetic regulation of redox balance and iron metabolism. | EXCLI J | 2026 | https://conductscience.org/library/papers/42517085 | PubMed |
| 42478333 | Expression Levels of DNMT1, HDAC1, and MT1E Genes as Diagnostic Biomarkers for Breast Cancer Clinicopathological Features: In Vitro and In Silico Analyses. | Anal Cell Pathol (Amst) | 2026 | https://conductscience.org/library/papers/42478333 | PubMed |
| 42290054 | [Potential Mechanisms and Research Advances of HDAC1 in Lung Cancer]. | Zhongguo Fei Ai Za Zhi | 2026 | https://conductscience.org/library/papers/42290054 | PubMed |
| 42199345 | Epigenetic dysregulation in mycosis fungoides and sézary syndrome. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42199345 | PubMed |
| 42059134 | Development of Biphenyl-Substituted Uracil-Based Hydroxamic Acids (UBHAs) as Potent HDAC Inhibitors with Pro-Apoptotic Activity in Leukemia and Prostate Cancer Cells. | J Med Chem | 2026 | https://conductscience.org/library/papers/42059134 | PubMed |
| 41957661 | Deciphering epigenetic crosstalk in multiple myeloma pathogenesis and treatment. | Clin Epigenetics | 2026 | https://conductscience.org/library/papers/41957661 | PubMed |
| 41828436 | Overcoming Chemoresistance in Glioblastoma: Mechanisms, Therapeutic Strategies, and Functional Precision Medicine. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41828436 | PubMed |
| 41783166 | Histone deacetylases: Function in tumor development and therapeutic prospects (Review). | Oncol Lett | 2026 | https://conductscience.org/library/papers/41783166 | PubMed |
| 41686481 | Structure-activity insights and molecular modeling approaches of anti-TNBC agents: a comprehensive systematic review. | Future Sci OA | 2025 | https://conductscience.org/library/papers/41686481 | PubMed |
| 41593801 | Differential transcriptomic modulation by histone deacetylase inhibitor SAHA in LUAD and LUSC. | Clin Epigenetics | 2026 | https://conductscience.org/library/papers/41593801 | PubMed |
| 41498889 | Role of HDAC6 in carcinomas. | Discov Oncol | 2026 | https://conductscience.org/library/papers/41498889 | PubMed |
| 41465319 | Microenvironmental and Molecular Pathways Driving Dormancy Escape in Bone Metastases. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41465319 | PubMed |
| 41463266 | In Vitro and In Vivo Efficacy of Romidepsin Alone and in Addition to Standard of Care for Treatment of Ewing Sarcoma. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41463266 | PubMed |
| 41452386 | Epigenomic landscape of nasopharyngeal carcinoma. | Med Oncol | 2025 | https://conductscience.org/library/papers/41452386 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| HDAC9 | 9734 | PubTator's text mining | https://conductscience.org/library/genes/9734 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40260239
GET https://conductscience.org/api/papers/v1/40260239/references?page=2